Phase I/II study of c-MET inhibitor (DE605) combined with sorafenib in patients with advanced hepatocellular carcinoma
Background: DE605 is a c-MET inhibitor that can be taken orally. Sorafenib is the only treatment that has been proven to increase overall survival rates in patients with advanced hepatocellular carcinoma (HCC). However, the effectiveness of sorafenib in a clinical setting is limited. By targeting multiple signaling pathways through combination therapy, patient outcomes may improve. This study aimed to establish the maximum tolerated dose (MTD) of DE605 when administered alongside sorafenib and to assess the safety and efficacy of this combination in treating patients with advanced HCC.
Patients and methods: Patients with advanced HCC received treatment that combined increasing doses of DE605 and sorafenib. The first phase of the study aimed to establish the MTD of this combination. In the second phase, patients were treated with the MTD to assess the safety and effectiveness of the treatment.
Results: In the first phase of the study, 27 patients were treated with sorafenib and increasing doses of DE605. In the second phase, 32 patients were enrolled. The MTD was determined to be 240 mg of DE605 once daily (QD) in combination with 400 mg of sorafenib twice daily (BID). Of the patients treated with the MTD, 9.4% had a partial response, 65.6% had stable disease, and 25% had progressive disease. The median time to progression was 2.5 months and the median overall survival was 11.6 months.
Conclusion: The combination of 240 mg of DE605 QD and the standard dose of 400 mg of sorafenib BID showed significant clinical effectiveness in treating patients with advanced HCC. The early indications of antitumor activity suggest that further development of this combination therapy may be warranted.
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100(10): 698–711. doi: 10.1093/jnci/djn134
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893–917. doi: 10.1002/ijc.25516
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099–109. doi: 10.1158/0008-5472.CAN-04-1443
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–90. doi: 10.1056/NEJMoa0708857
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25–34. doi: 10.1016/S1470-2045(08)70285-7
Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53(3): 1020–2. doi: 10.1002/hep.24199
LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11(1–2): 32–50. doi: 10.1016/j.drup.2007.11.003
Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48(4): 1312–27. doi: 10.1002/hep.22506
Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7(6): 504–16. doi: 10.1038/nrd2530
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15(7): 2207–14. doi: 10.1158/1078-0432.CCR-08-1306
Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A 2004; 101(29): 10608–13. doi: 10.1073/pnas.0403412101
Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G, LaRochelle WJ. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ 1996; 7(11): 1513–23.
Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res 2012; 35(4): 595–604. doi: 10.1007/s12272-012-0402-6
You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011; 54(3): 879–89. doi: 10.1002/hep.24450
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natal Acad Sci U S A 2007; 104(37): 14771–6. doi: 10.1073/pnas.0706578104
Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001; 153(5): 1023–34. doi: 10.1083/jcb.153.5.1023
Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, et al. Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res 2013; 32: 16. doi: 10.1186/1756-9966-32-16
Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008; 44(5): 641–51. doi: 10.1016/j.ejca.2008.01.022
Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010; 16(13): 3507–16. doi: 10.1158/1078-0432.CCR-10-0574
Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget 2014; 5(7): 1837–45. doi: 10.18632/oncotarget.1828
Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011; 29(10): 1271–9. doi: 10.1200/JCO.2010.31.0367
Pant S, Saleh M, Bendell J, Infante JR, Jones S, Kurkjian CD, et al. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol 2014; 25(7): 1416–21. doi: 10.1093/annonc/mdu157
Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, et al. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs 2015; 33(1): 159–68. doi: 10.1007/s10637-014-0167-5
Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, et al. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br J Cancer 2013; 109(11): 2803–9. doi: 10.1038/bjc.2013.588
Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 2011; 5(3): 850–6. doi: 10.1007/s12072-010-9249-4
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27(20): 3312–8. doi: 10.1200/JCO.2008.19.5511
Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99(1): 159–65.
Furuse J, Okusaka T, Kaneko S, Kudo M, Nakachi K, Ueno H, et al. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci 2010; 101(12): 2606–11. doi: 10.1111/j.1349-7006.2010.01730.x
Copyright (c) 2023 Bahar Karayel, Sena Durgun, Orhan Öcalgiray
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain full copyright to their individual works, and publishing rights without restrictions.
In accordance with the Budapest Open Access Initiative, articles published in STEMedicine are freely available "on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited."
Except where otherwise noted, all content on this website is licensed under a Creative Commons Attribution 4.0 License. This license allows for commercial and non-commercial redistribution as well as modifications of the work as long as attribution is given to the authors and STEMedicine as the original publication source, and a link to the article on the STEMedicine website is provided.